News

Estonian startup Gelatex makes entry to advanced 3D cell culture and tissue engineering field with Gelacell™

Estonian startup Gelatex makes entry to advanced 3D cell culture and tissue engineering field with Gelacell™
Gelacell™ is a product line designed to revolutionize 3D cell culture and tissue engineering.
Estonia
Ecosystems
Ecosystems

This year Gelatex, a pioneering Estonian materials technology startup at the forefront of innovative biomaterials, launched Gelacell™ – a product line designed to revolutionize 3D cell culture and tissue engineering.

Gelacell™ introduces a non-woven, highly porous scaffold with a unique nanofibrous structure that closely mimics the natural extracellular matrix, fostering exceptional biocompatibility and non-toxicity across various cell types.

“Our Gelacell™ line represents a significant leap forward in the realm of in vitro cell culture and tissue engineering,” stated Märt-Erik Martens, CEO of Gelatex. “Its morphological advantages, including high surface-to-volume ratio, biomimicry, and enhanced cell interactions, open doors for diverse applications in biomedical research that were previously closed.”

Central to Gelacell™ is the novel halospinning technology, a patented high-throughput method that ensures cost-effectiveness and continuous production of nanofibers. This innovative solution-spinning method, described in the patent US 11,697,892, surpasses traditional electrospinning practices in speed and efficiency as well as helps provide a true 3D environment for the cells.

The launch preceded with rigorous in-house testing in the cell lab which Gelatex used to verify the potential of Gelacell™. Fibroblast and myoblast cells showcased uniform growth, exhibiting formations akin to in vivo tissue characteristics. The halospun nanofibrous scaffolds notably supported cell-to-cell and cell-to-scaffold interactions, fostering enhanced cell proliferation and differentiation.

The transition from traditional 2D in vitro systems to Gelacell™’s 3D scaffold heralds a paradigm shift in cell culture methodology. Unlike the flattening and stretching observed in 2D systems, the 3D scaffold preserves the natural shape of cells, reducing stress conditions and facilitating a structural conformation similar to native tissues. This preservation of cell functions, surface activity, and interactions opens doors to several potential applications:

  • Cardiotoxicology: Gelacell™’s aligned scaffolds significantly improve structural and functional read-outs in cardiomyocytes, showcasing faster kinetics and enhanced performance compared to standard 2D culture plates.
  • Toxicology Studies: Nanofiber scaffolds provide an ideal environment for Hep G2 liver cancer cells, serving as a model culture for in-vitro toxicology studies.
  • Drug Discovery in 3D Tissue Models: Cancer cells cultured in 3D environments exhibit increased drug resistance compared to traditional 2D systems. Gelacell™’s nanofiber scaffolds have proven successful in various cancer cell models, aiding in more physiologically relevant drug screening.
  • Stem cell research: facilitating the differentiation of neural stem cells into mature neurons within nanofiber scaffolds.

The launch of Gelacell™ underscores Gelatex’s commitment to advancing the landscape of cell culture and tissue engineering, offering researchers and scientists a transformative tool for a myriad of applications.

NEWS​

Related News

July 2024 ECHAlliance Newsletter

24 Jul 2024

Cross-sector collaboration positions West Yorkshire as global leader in healthtech innovation

24 Jul 2024
West Yorkshire’s health, care and academic leaders signed a Memorandum of Understanding with with the Association of British HealthTech Industries (AB...

Strata Health Launches Booking and Referral Standard (BaRS) at NHS East Lancashire Hospitals

24 Jul 2024
Thousands of referrals have passed through our integration to create appointments in Strata PathWays, which has already made a huge impact within the ...

Envisioning seamless sharing of digital meds data in Wales

24 Jul 2024
Digital Health and Care Wales (DHCW) is embarking on the creation of a shared medicines record for the whole of the country. The Digital Medicines Tra...

One of Europe’s leading university hospitals selects Better technology for its core data platform

24 Jul 2024
Following a framework procurement issued in 2023, one of Europe's leading university hospitals has completed the first call-off for openEHR software, ...

BioTech Sphere Research: The organisation that empowers progress and access in India

24 Jul 2024
Learn more about the latest member to join our global community: BioTech Sphere Research.

Become a member

Join ECHAlliance to amplify your organisation’s message, grow your networks, connect with innovators and collaborate globally.
 
First name *
Last Name *
Email Address *
Country *
Position *
First name *
Last Name *
Email Address *
Country *
Position *